These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995 [TBL] [Abstract][Full Text] [Related]
6. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation. Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660 [TBL] [Abstract][Full Text] [Related]
8. SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Bu Q; Cui L; Li J; Du X; Zou W; Ding K; Pan J Cancer Biol Ther; 2014 Jul; 15(7):951-62. PubMed ID: 24759597 [TBL] [Abstract][Full Text] [Related]
9. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636 [TBL] [Abstract][Full Text] [Related]
10. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Nguyen TK; Rahmani M; Harada H; Dent P; Grant S Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385 [TBL] [Abstract][Full Text] [Related]
11. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia. Shao S; Li S; Qin Y; Wang X; Yang Y; Bai H; Zhou L; Zhao C; Wang C Int J Oncol; 2014 May; 44(5):1661-8. PubMed ID: 24585095 [TBL] [Abstract][Full Text] [Related]
12. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells. Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096 [TBL] [Abstract][Full Text] [Related]
14. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422 [TBL] [Abstract][Full Text] [Related]
16. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333 [TBL] [Abstract][Full Text] [Related]
17. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Chu S; Holtz M; Gupta M; Bhatia R Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699 [TBL] [Abstract][Full Text] [Related]
18. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. O'Hare T; Eide CA; Agarwal A; Adrian LT; Zabriskie MS; Mackenzie RJ; Latocha DH; Johnson KJ; You H; Luo J; Riddle SM; Marks BD; Vogel KW; Koop DR; Apgar J; Tyner JW; Deininger MW; Druker BJ Cancer Res; 2013 Jun; 73(11):3356-70. PubMed ID: 23576564 [TBL] [Abstract][Full Text] [Related]